CN103012421B - Iloquinoline derivative medicine and preparation thereof and purposes - Google Patents
Iloquinoline derivative medicine and preparation thereof and purposes Download PDFInfo
- Publication number
- CN103012421B CN103012421B CN201210521407.XA CN201210521407A CN103012421B CN 103012421 B CN103012421 B CN 103012421B CN 201210521407 A CN201210521407 A CN 201210521407A CN 103012421 B CN103012421 B CN 103012421B
- Authority
- CN
- China
- Prior art keywords
- hydrate
- berbamine
- preparation
- berbamine hydrochloride
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 36
- 206010002660 Anoxia Diseases 0.000 claims abstract description 7
- 241000976983 Anoxia Species 0.000 claims abstract description 7
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 7
- 201000010001 Silicosis Diseases 0.000 claims abstract description 7
- 230000007953 anoxia Effects 0.000 claims abstract description 7
- 230000003288 anthiarrhythmic effect Effects 0.000 claims abstract description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 7
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 7
- 206010020718 hyperplasia Diseases 0.000 claims abstract description 7
- 230000000302 ischemic effect Effects 0.000 claims abstract description 7
- 201000008827 tuberculosis Diseases 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 5
- 208000001953 Hypotension Diseases 0.000 claims abstract description 4
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 4
- 201000011510 cancer Diseases 0.000 claims abstract description 4
- 238000002512 chemotherapy Methods 0.000 claims abstract description 4
- 208000021822 hypotensive Diseases 0.000 claims abstract description 4
- 230000001077 hypotensive effect Effects 0.000 claims abstract description 4
- 210000000265 leukocyte Anatomy 0.000 claims abstract description 4
- 238000001959 radiotherapy Methods 0.000 claims abstract description 4
- 230000002265 prevention Effects 0.000 claims abstract 3
- 201000010099 disease Diseases 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 2
- DFOCUWZXJBAUSQ-URLMMPGGSA-N Berbamine Chemical group C([C@@H]1N(C)CCC=2C=C(C(OC=3C(OC)=C(OC)C=C4CCN(C)[C@@H](C=34)CC=3C=C(C(=CC=3)O)O3)=CC=21)OC)C1=CC=C3C=C1 DFOCUWZXJBAUSQ-URLMMPGGSA-N 0.000 claims description 89
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 49
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000007787 solid Substances 0.000 claims description 21
- 238000003756 stirring Methods 0.000 claims description 20
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 16
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
- 239000003826 tablet Substances 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- DFOCUWZXJBAUSQ-UHFFFAOYSA-N Berbamine Natural products O1C(C(=CC=2)O)=CC=2CC(C=23)N(C)CCC3=CC(OC)=C(OC)C=2OC(=CC=23)C(OC)=CC=2CCN(C)C3CC2=CC=C1C=C2 DFOCUWZXJBAUSQ-UHFFFAOYSA-N 0.000 claims description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 239000002775 capsule Substances 0.000 claims description 10
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 239000008187 granular material Substances 0.000 claims description 8
- 150000002576 ketones Chemical class 0.000 claims description 8
- 238000001953 recrystallisation Methods 0.000 claims description 8
- 238000001035 drying Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 238000002347 injection Methods 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 6
- 238000002425 crystallisation Methods 0.000 claims description 4
- 230000008025 crystallization Effects 0.000 claims description 4
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000002496 gastric effect Effects 0.000 claims description 3
- 239000002904 solvent Substances 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 claims 10
- 241001465754 Metazoa Species 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 238000003860 storage Methods 0.000 abstract description 3
- 238000000034 method Methods 0.000 description 29
- 239000000047 product Substances 0.000 description 20
- 238000004458 analytical method Methods 0.000 description 19
- 239000000243 solution Substances 0.000 description 19
- 150000003839 salts Chemical class 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- 235000019441 ethanol Nutrition 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 239000013078 crystal Substances 0.000 description 10
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000012085 test solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- -1 Berbamine hydrochloride anhydride Chemical class 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000000108 ultra-filtration Methods 0.000 description 8
- 239000008215 water for injection Substances 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 239000003981 vehicle Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000003889 eye drop Substances 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- 229930195725 Mannitol Natural products 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 5
- 239000000594 mannitol Substances 0.000 description 5
- 235000010355 mannitol Nutrition 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 150000002825 nitriles Chemical class 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 5
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 238000007907 direct compression Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 238000005374 membrane filtration Methods 0.000 description 4
- 239000003002 pH adjusting agent Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 241000972773 Aulopiformes Species 0.000 description 3
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 3
- UEJQQMLXZQUJHF-UHFFFAOYSA-L [K+].[I+].[I-].[I-] Chemical compound [K+].[I+].[I-].[I-] UEJQQMLXZQUJHF-UHFFFAOYSA-L 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- 238000005262 decarbonization Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000002329 infrared spectrum Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 150000003016 phosphoric acids Chemical class 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 235000019515 salmon Nutrition 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 238000001291 vacuum drying Methods 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 2
- BJWWOUUGCAPHOV-UHFFFAOYSA-N 1,3-dibenzylisoquinoline Chemical class C=1C2=CC=CC=C2C(CC=2C=CC=CC=2)=NC=1CC1=CC=CC=C1 BJWWOUUGCAPHOV-UHFFFAOYSA-N 0.000 description 2
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 2
- PMNLUUOXGOOLSP-UHFFFAOYSA-N 2-mercaptopropanoic acid Chemical compound CC(S)C(O)=O PMNLUUOXGOOLSP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 239000004368 Modified starch Substances 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000003513 alkali Substances 0.000 description 2
- 150000008064 anhydrides Chemical class 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 2
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 2
- 229940043276 diisopropanolamine Drugs 0.000 description 2
- WQABCVAJNWAXTE-UHFFFAOYSA-N dimercaprol Chemical compound OCC(S)CS WQABCVAJNWAXTE-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- GNTDGMZSJNCJKK-UHFFFAOYSA-N divanadium pentaoxide Chemical compound O=[V](=O)O[V](=O)=O GNTDGMZSJNCJKK-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 201000002364 leukopenia Diseases 0.000 description 2
- 231100001022 leukopenia Toxicity 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000019426 modified starch Nutrition 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229960001462 sodium cyclamate Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 229920003109 sodium starch glycolate Polymers 0.000 description 2
- 229940079832 sodium starch glycolate Drugs 0.000 description 2
- 239000008109 sodium starch glycolate Substances 0.000 description 2
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- HXKKHQJGJAFBHI-UHFFFAOYSA-N 1-aminopropan-2-ol Chemical compound CC(O)CN HXKKHQJGJAFBHI-UHFFFAOYSA-N 0.000 description 1
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- QQZOPKMRPOGIEB-UHFFFAOYSA-N 2-Oxohexane Chemical compound CCCCC(C)=O QQZOPKMRPOGIEB-UHFFFAOYSA-N 0.000 description 1
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000143437 Aciculosporium take Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- FITPCXSHEGAMCJ-JJKGCWMISA-N ClC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na] Chemical compound ClC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[Na] FITPCXSHEGAMCJ-JJKGCWMISA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
- JPIJQSOTBSSVTP-GBXIJSLDSA-N D-threonic acid Chemical compound OC[C@@H](O)[C@H](O)C(O)=O JPIJQSOTBSSVTP-GBXIJSLDSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- KGWDUNBJIMUFAP-KVVVOXFISA-N Ethanolamine Oleate Chemical compound NCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KGWDUNBJIMUFAP-KVVVOXFISA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical group OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- WGYFACNYUJGZQO-UHFFFAOYSA-N aminomethanetriol Chemical compound NC(O)(O)O WGYFACNYUJGZQO-UHFFFAOYSA-N 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000003289 ascorbyl group Chemical class [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229940046011 buccal tablet Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 229960001305 cysteine hydrochloride Drugs 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229960001051 dimercaprol Drugs 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- GRWZHXKQBITJKP-UHFFFAOYSA-N dithionous acid Chemical compound OS(=O)S(O)=O GRWZHXKQBITJKP-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 229940026231 erythorbate Drugs 0.000 description 1
- 235000010350 erythorbic acid Nutrition 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000010439 graphite Substances 0.000 description 1
- 229910002804 graphite Inorganic materials 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000020169 heat generation Effects 0.000 description 1
- JVQUBHIPPUVHCN-UHFFFAOYSA-N hexane-1,2-diamine Chemical compound CCCCC(N)CN JVQUBHIPPUVHCN-UHFFFAOYSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 229930013397 isoquinoline alkaloid Natural products 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 239000012982 microporous membrane Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- KWUZCAVKPCRJPO-UHFFFAOYSA-N n-ethyl-4-(6-methyl-1,3-benzothiazol-2-yl)aniline Chemical compound C1=CC(NCC)=CC=C1C1=NC2=CC=C(C)C=C2S1 KWUZCAVKPCRJPO-UHFFFAOYSA-N 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002898 organic sulfur compounds Chemical class 0.000 description 1
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- WSHYKIAQCMIPTB-UHFFFAOYSA-M potassium;2-oxo-3-(3-oxo-1-phenylbutyl)chromen-4-olate Chemical compound [K+].[O-]C=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 WSHYKIAQCMIPTB-UHFFFAOYSA-M 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000011146 sterile filtration Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- ZIWHWEYDKGWAOG-ZIDSAKIASA-H tricalcium (2R,3R,4S,5R,6S)-2-(hydroxymethyl)-6-[(2R,3S,4R,5R)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol diphosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@H]1[C@H](O)[C@@H](O)C(O)O[C@@H]1CO ZIWHWEYDKGWAOG-ZIDSAKIASA-H 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- JFJZZMVDLULRGK-URLMMPGGSA-O tubocurarine Chemical compound C([C@H]1[N+](C)(C)CCC=2C=C(C(=C(OC3=CC=C(C=C3)C[C@H]3C=4C=C(C(=CC=4CCN3C)OC)O3)C=21)O)OC)C1=CC=C(O)C3=C1 JFJZZMVDLULRGK-URLMMPGGSA-O 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to iloquinoline derivative medicine and its production and use, its molecular formula is C
37h
40n
2o
62HClnH
2o, wherein, n=3,3.5.This iloquinoline derivative medicine has good storage stability, is applicable to prepare the application in the treatments of disease such as promoting leucocyte hyperplasia, preventing cancer radiotherapy, Leukocytes after Chemotherapy minimizing, anti-inflammatory, tuberculosis, anti-silicosis, antitumor, hypotensive, anti-myocardial anoxia ischemic, anti-arrhythmia or the medicine of prevention.
Description
Technical field
The present invention relates to medical art, be specifically to provide the bisbenzylisoquinoline alkaloid effect of berbamine derivative and preparation thereof and purposes that have and promote the effects such as leucocyte hyperplasia, anti-inflammatory, hypertension, anti-myocardial anoxia ischemic, anti-arrhythmia, tuberculosis, antitumor, anti-silicosis.
Background technology
Berbamine system isoquinoline alkaloid, has effects such as promoting leucocyte hyperplasia, anti-inflammatory, hypertension, anti-myocardial anoxia ischemic, anti-arrhythmia, tuberculosis, antitumor, anti-silicosis.Disclosed document only reports Berbamine hydrochloride [C at present
37h
40n
2o
62HCl, molecular weight: 681.65], and the pharmacology of Berbamine and clinical application situation, as document: pharmaceutical action of EBB analysis [Tropical China medical science 2005,5 (1): 109-110)], cardiovascu-lar effects progress [the Chinese combination of Chinese tradiational and Western medicine magazine of Berbamine, 2005, ] etc., but up to the present, still there is no disclosed bibliographical information Berbamine hydrochloride crystalline hydrate of the present invention [C both at home and abroad 25 (8): 765-768)
37h
40n
2o
62HClnH
2o, wherein n=3.0,3.5] and its production and use.
Summary of the invention
Involved in the present invention is has the bisbenzylisoquinoline alkaloid effect of berbamine derivative promoting the effect such as leucocyte hyperplasia, anti-inflammatory, hypertension, anti-myocardial anoxia ischemic, anti-arrhythmia, tuberculosis, antitumor, anti-silicosis, i.e. Berbamine hydrochloride crystalline hydrate and preparation thereof and purposes.Its molecular formula is C
37h
40n
2o
62HClnH
2o, wherein, n=3,3.5.
The Berbamine hydrochloride crystalline hydrate containing crystal water that the present invention obtains, surprisingly, Berbamine hydrochloride hydrate containing crystal water draws moist far below Berbamine hydrochloride anhydride, Berbamine hydrochloride hydrate containing crystal water more can be stable than Berbamine hydrochloride anhydride existence, be convenient to store and transport, be easy to make preparation.In addition, the deliquescence of anhydride makes will to completely cut off air when processing and prevents adhesion etc., and crystalline hydrate has good sliding, thus improves the operability of preparation.Moreover crystalline solid has chemical stability higher than amorphous form and low-crystallinity form and physical stability, they also can show as the water absorbability of raising, bulk properties and or mobility.
Distinctive, thermal analyses (TG-DTA etc.) collection of illustrative plates of hydrate of the present invention can find out that weightless platform has the endotherm(ic)peak of strong correspondence, and thermal analyses collection of illustrative plates demonstrates Berbamine hydrochloride crystalline hydrate [C
37h
40n
2o
62HCl3H
2o], [C
37h
40n
2o
62HCl3.5H
2o], match by Karl_Fischer method mensuration moisture result and thermal analyses result.
The discovery of the useful compound on the medicine of new crystal provides new chance once improving the action characteristic of medicament production, it expands the storehouse of formulation science man design example as the pharmaceutical dosage form and the material obtained with the medicine of targeted release profile or other desired characteristic, and this area needs Berbamine hydrochloride crystalline hydrate or its polymorph.
Surprisingly, distinctive, have corresponding endotherm(ic)peak under the weightless platform of thermal analyses (TG-DSC or the TG-DTA) collection of illustrative plates of hydrate of the present invention, thermal analyses collection of illustrative plates demonstrates Berbamine hydrochloride crystalline hydrate etc.
Berbamine hydrochloride crystalline hydrate of the present invention, for off-white color is to pale yellow powder, can stable storage.By above-mentioned Berbamine hydrochloride crystalline hydrate matter sample respectively airtight with cillin bottle in carry out accelerated stability test, with reference to the content assaying method of China National Drug Standard [WS-10001-(HD-1242)-2002], measure Berbamine hydrochloride crystalline hydrate prepared by various embodiments of the invention, have been surprisingly found that, the content of Berbamine hydrochloride 3 hydrate of the present invention does not have considerable change (30 DEG C, under RH75%).The results are shown in Table 1.
Table 1. Berbamine hydrochloride hydrate of the present invention accelerated stability test different time sampling result
Chromatographic condition (the chromatographic condition: chromatographic column: C of reference literature [Du Zhimao etc., Chinese Journal of Pharmaceuticals, 2005,36 (1): 4041]
l8(150mm × 4.6mm, 5 μm); Moving phase: acetonitrile-0.02mol/L potassium dihydrogen phosphate [phosphorus acid for adjusting pH is to 7.0] (70:30); Flow velocity: lml/min; Temperature: 35 DEG C; Determined wavelength: 282nm), the content of Berbamine hydrochloride 3 hydrate of the present invention and related substance do not have considerable change (30 DEG C, under RH75%), illustrate that Berbamine hydrochloride crystalline hydrate of the present invention has better storage stability.
Isoquinilone derivatives---Berbamine hydrochloride crystalline hydrate is preparation method comprise:
Method A. takes Berbamine or Berbamine solvate crude product, is added to the water of 2-12 times amount, C
1-C
6low mass molecule alcohol in one or more reaction vessels in, add hydrochloric acid soln, be stirred to dissolve, regulate (preferable ph is about 2.6) between pH to 1.0-3.5, add proper amount of active carbon, stir, filter, filtrate is alkalized, precipitation is fully separated out, filter, by gained solid, add hydrochloric acid soln, be stirred to dissolve, between adjust ph to 1.2-3.5 (preferable ph is about 2.6), add proper amount of active carbon, stir, filter, gained filtrate is concentrated, by gained filtrate C
1-C
6low mass molecule alcohol, C
2-C
6rudimentary nitrile, C
3-C
8low molecule ketone in one or more recrystallizations, cooling, place, precipitation is fully separated out, filter, gained solid drying, obtains Berbamine hydrochloride crystalline hydrate; By gained Berbamine hydrochloride crystalline hydrate water and C
1-C
6low mass molecule alcohol, C
2-C
6rudimentary nitrile, C
3-C
8low molecule ketone in one or more, one or many recrystallization operation can be carried out further.
Or method B., by Berbamine or Berbamine solvate, is added to the water of 2-12 times amount, C
1-C
6low mass molecule alcohol in one or more reaction vessels in, add hydrochloric acid soln, be stirred to dissolve, between adjust ph to 1.0-3.5 (preferable ph is about 2.6), add proper amount of active carbon, stir, filter, filtrate is concentrated, in filtrate, adds C
1-C
6low mass molecule alcohol, C
2-C
6rudimentary nitrile, C
3-C
8low molecule ketone in one or more, cooling, make crystallization, filter, with water, the C of less than 0 DEG C
2-C
6rudimentary ether, by gained solid drying, obtain Berbamine hydrochloride crystalline hydrate; By gained Berbamine hydrochloride crystalline hydrate water and C
1-C
6low mass molecule alcohol, C
2-C
6rudimentary nitrile, C
3-C
8low molecule ketone in one or more, one or many recrystallization operation can be carried out further.
One or more preferably in: water and methyl alcohol, ethanol, Virahol, acetonitrile, ether, acetone, hexone, methylene dichloride of the crystallization of product of the present invention or recrystallization solvent.
Lower alcohol in the present invention or the carbonatoms of low mass molecule alcohol are defined as C
1-C
6(that is: the alcohol of 1-6 carbon atom), as methyl alcohol, ethanol, Virahol, butanols etc.; C
2-C
6the carbonatoms of rudimentary nitrile be defined as C
2-C
6, as acetonitrile, propionitrile etc.; C
3-C
8low molecule ketone be defined as the ketone of 3-8 carbon atom, comprise acetone, butanone, pentanone, hexanone, hexone etc.; The carbonatoms of rudimentary ether or low molecule ether is defined as C
2-C
8, as ether, isopropyl ether, butyl ether etc.; Be described as " low molecule ", " rudimentary " as long as the marking method of the amount of carbon atom of compound occurs once in the text of the application about any class, other any unmarked carbonatoms being described as the similar compound of " low molecule " is consistent with the quantity indicated herein.
The drying mode of product of the present invention can for differing temps (as 10-80 DEG C), time of drying (1 hour to a few days) or with the envrionment conditions of other siccative (comprising silica gel, Vanadium Pentoxide in FLAKES, Calcium Chloride Powder Anhydrous, anhydrous sodium sulphate etc.) under or use the mode of normal pressure or decompression to carry out drying to last product.Its drying temperature preferably 50 DEG C or within.
Moisture determination of the present invention adopts Karl_Fischer method.The fusing point of Berbamine hydrochloride hydrate of the present invention measures at different time melting point apparatus, and melting point detector corrects.
Powder X-ray diffraction can be used to characterize and/or differentiate polymorph usually, for powder X-ray diffraction when characterizing and/or differentiate, before report peak value, uses modifier " about ".In view of the intrinsic change of peak value, this is the practice of solid-state chemical arts.The usual accuracy of the 2 θ x-axle values at powder collection of illustrative plates peak in ± 0.2 ° of 2 θ rank, therefore, so that " the powder X-ray diffraction peak that about 8.0 ° of 2 θ occurs means when measuring on most of x-ray diffractometer, and peak may between 7.8 ° of 2 θ and 8.2 ° of 2 θ.The change of peak intensity is each crystal result relative to external X-ray source how orientation in sampling receptacle, and orientation effect does not provide the structural information about crystal.
The present invention on the one hand, provides the different crystalline hydrate of Berbamine hydrochloride.
The present invention on the other hand, the preparation method of the crystalline hydrate providing Berbamine hydrochloride different.
The present invention provides a kind of medicinal compositions on the other hand, comprising any one or the multiple Berbamine hydrochloride hydrate prepared by method of the present invention, and the acceptable vehicle of one or more pharmacy.
The present invention further provides the method for useful in preparing drug formulations, comprising the merging of any one or the multiple Berbamine hydrochloride hydrate prepared by method of the present invention and at least one or the acceptable vehicle of pharmacy.
The present invention further provides Berbamine hydrochloride hydrate, for the preparation for the treatment of people or mammiferous promotion leucocyte hyperplasia, the leukopenia caused for a variety of causes, for the purposes in the treatment such as preventing cancer radiotherapy, Leukocytes after Chemotherapy minimizings, anti-inflammatory, tuberculosis, anti-silicosis, antitumor, hypotensive, anti-myocardial anoxia ischemic, anti-arrhythmia or the pharmaceutical composition that prevents.
Berbamine hydrochloride hydrate of the present invention can be used for preparing solid preparation, comprises the application in tablet, capsule etc.
The solid preparation of Berbamine hydrochloride hydrate of the present invention comprises tablet, capsule, granule etc.; Tablet (comprising ordinary tablet, buccal tablet, fast disintegrating tablet, effervescent tablet etc.), capsule (comprising capsule for vagina), granule, wherein can contain pharmaceutically acceptable weighting agent, as starch, modified starch, lactose, Microcrystalline Cellulose, cyclodextrin, sorbyl alcohol, N.F,USP MANNITOL, calcium phosphate, amino acid etc.; Pharmaceutically acceptable disintegrating agent, as starch, modified starch, Microcrystalline Cellulose, sodium starch glycolate, cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, tensio-active agent (sodium lauryl sulphate etc.); Pharmaceutically acceptable wetting agent and tackiness agent, as gelling starch, methylcellulose gum, Xylo-Mucine, ethyl cellulose, polyvinylpyrrolidone, Lalgine and salt thereof; Pharmaceutically acceptable lubricant and glidant, as stearic acid, Magnesium Stearate, Macrogol 4000-8000, talcum powder, micropowder silica gel, Stepanol MG etc.; Pharmaceutically acceptable sweeting agent and essence, as aspartame, Sodium Cyclamate, soluble saccharin, Sucralose, food flavour etc.
Obtaining composition for the preparation of tablet or capsule filling can by wet granulation in preparation, in wet-granulation process, the activeconstituents of some or all or the vehicle of powder type mixed, and then mix further under the existence of liquid, this causes powder grumeleuse to become particle.This particle is sieved and or grinding, dry, then sieve, to the granularity expected, then this particle can make tablet, or before preparation, add other vehicle, such as glidant and/or lubricant.
The composition being prepared into tablet can be prepared by being dry mixed usually.Such as, the composition after activeconstituents and mixed with excipients can be compacted into as small pieces or thin slice, and be then ground into the particle of compacting, the particle of this compacting can be suppressed into tablet subsequently.
Substituting as dry granular method, mixed composition can dry method direct compression, direct compression obtain evenly tablet.The vehicle being particularly suitable for direct compression comprises Microcrystalline Cellulose, spray-dired lactose calcium phosphate and colloid silica.These and other vehicle is proper use of in direct compression is be known to the technician in this area with experience and technical ability.
Capsule filling of the present invention can comprise any above-mentioned mixture and particle or particle, and it describes with reference to being prepared into tablet, but they do not carry out the last step being prepared into tablet.
The deliquescence that crystalline hydrate of the present invention is different from anhydride makes will to completely cut off air when processing and prevents adhesion etc., and crystalline hydrate has good sliding, thus improves the operability of preparation; And make the solid preparation of preparation have good dissolving out capability, make it easily be rapidly absorbed into blood circulation, improve bioavailability, and be conducive to its effect of fast onset.
Prepared by dosing eyes preparation
In the preparation of Berbamine hydrochloride crystalline hydrate eye drop, the parts by weight of each component can be: Berbamine hydrochloride crystalline hydrate 0.1-1, solubility promoter 0.1-1, antioxidant 0.02-0.5, metal chelating agent 0.01-0.2, osmotic pressure regulator 0.5-10, sanitas 0.002-0.4, water is 10-100 part, separately adds pH adjusting agent appropriate.
Its preparation method can be: added by Berbamine hydrochloride hydrate in appropriate water for injection, add solubility promoter, stir, examination is dissolved, add oxidation inhibitor, sanitas, osmotic pressure regulator, stablizer, pH adjusting agent, water, stirs, and becomes solution shape, make pH=5.0-7.0, filter in the mode such as millipore filtration or ultrafiltration, detect, aseptic subpackaged in sterilized clean plastics eyedrops bottle and get final product.
Berbamine hydrochloride hydrate injection, its preparation method is:
The preparation method of freeze-dried powder is: get Berbamine hydrochloride hydrate, can add pharmaceutically acceptable frozen-dried supporting agent or auxiliary shape agent, injects with water, add pharmaceutically acceptable soda acid, be stirred to dissolve, regulate pH to be 2.0 ~ 5.5, add activated carbon 0.005 ~ 0.5%(W/V) stir 15 ~ 45min, filter, moisturizing, sterile filtration, by 20 ~ 600mg/ bottle (in main ingredient) packing, lyophilize, tamponade, obtains finished product.
Berbamine hydrochloride hydrate injection with small volume and preparation technology thereof: Berbamine hydrate injects with water and pharmaceutically acceptable additives, such as: pharmaceutically acceptable pH adjusting agent, pharmaceutically acceptable oxidation inhibitor, rare gas element, filter, degermingly make sterilizing injection with small volume, its pH value is between 2.0 ~ 5.5.
Pharmaceutically acceptable pH adjusting agent can be pharmaceutically acceptable mineral acid or organic acid, mineral alkali or organic bases, also can be Lewis acid or the alkali of broad sense, one or several can be contained, can be hydrochloric acid, phosphoric acid, propionic acid, acetic acid and acetate, as sodium-acetate etc., lactic acid and lactic acid pharmaceutical salts, Citric Acid pharmaceutical salts, sodium carbonate, sodium bicarbonate, saleratus, sodium hydroxide, phosphoric acid salt, tartrate and pharmaceutical salts thereof, borax, boric acid, succinic acid, caproic acid, hexanodioic acid, FUMARIC ACID TECH GRADE, maleic acid, trihydroxy-aminomethane, diethanolamine, thanomin, α-amino isopropyl alcohol, diisopropanolamine (DIPA), 2-amino-2-(methylol) 1, ammediol amine, 1, 2-hexanediamine, N-methyl glucose amine, Diisopropylamine and their salt, multi-hydroxy carboxy acid and pharmaceutical salts, as glucuronic acid, gluconic acid, lactobionic acid, oxysuccinic acid, threonic acid, glucoheptonic acid, one or several in amino acid and amino acid salts etc.
Pharmaceutically acceptable oxidation inhibitor and stablizer can be sulfurous acid, sulphite, hydrosulphite, pyrosulfite, hyposulfite, thiosulphate, organosulfur compound thiocarbamide, gsh, dimercaprol dimercaptopropanol, Thiovanic acid and salt, thiolactic acid and pharmaceutical salts thereof, thio-2 acid and salt, phenol compound, as gallic acid and pharmaceutical salts thereof, coffic acid and pharmaceutical salts thereof, forulic acid and pharmaceutical salts thereof, di-t-butyl Pyrogentisinic Acid, 2, 5-resorcylic acid, 2, 5-resorcylic acid salt, phenol or derivatives thereof, Whitfield's ointment or its salt, amino acid and its salt, xitix and ascorbate salt, saccharosonic acid and erythorbate, niacinamide, tartrate, nitrate, phosphoric acid salt, acetic acid pharmaceutical salts, Citrate trianion, EDTA and edta salt, as one or several in EDETATE SODIUM, EDTA tetra-sodium, N-bis-(2-hydroxyethyl) glycine etc.
Pharmaceutically acceptable isotonic regulator can be one or more in glucose, fructose, Xylitol, sorbyl alcohol, N.F,USP MANNITOL, Nulomoline, maltose, dextran, sodium-chlor, Repone K, Sodium.alpha.-hydroxypropionate etc.
Source and the degerming mode of reducing phlegm and internal heat can be that the gac adding dosing amount 0.005 ~ 3% reduces phlegm and internal heat source, and the degerming and pressure sterilizing of millipore filtration, also can adopt heat sterilization, source of reducing phlegm and internal heat.In hyperfiltration process, ultra-fine filter can select flat, rolling, tubular type, hollow fiber form or circle boxlike etc., preferred rolling and hollow fiber form ultra-fine filter, adopt retain relative molecular mass be 5 ten thousand to 30 ten thousand filter membrane remove most of heat generation material and bacterium after, adopt the ultra-filtration membrane removing residue thermal source retaining relative molecular mass 3000 ~ 60000 again, the ultra-filtration membrane of preferred relative molecular mass 3000 ~ 20000.
Berbamine hydrochloride hydrate of the present invention, is applicable to prepare following to people or mammiferous promotion leucocyte hyperplasia, the leukopenia caused for a variety of causes, application for medicine aspects such as preventing cancer radiotherapy, Leukocytes after Chemotherapy minimizing, anti-inflammatory, tuberculosis, anti-silicosis, antitumor, hypotensive, anti-myocardial anoxia ischemic, anti-arrhythmias.
Consumption usage: generally, in adult; get the freeze-dried powder of Berbamine hydrochloride hydrate of the present invention 0.020 ~ 0.2g or little liquid drugs injection in 0.9% sodium-chlor or 5 ~ 10% glucose 20 ~ 500 milliliters; do intravenous injection or instillation; every day 1 ~ 2 time; 0.9% sodium-chlor of Berbamine hydrochloride hydrate or the route of administration of 5 ~ 10% glucose great transfusion preparations are intravenous injection, and dosage is the same; Intramuscularly: get medicine 0.020 ~ 0.2g freeze-dried powder of the present invention and be dissolved in water for injection, intramuscularly, every day 1 ~ 2 time; More than children's amount of reducing by half use.Through gastrointestinal administration dosage, be generally oral: 25-100mg/ time, 1-3 times/day, more than children's amount of reducing by half uses.The usage of eye drops: adult's usual amounts 0.1-1% Berbamine hydrochloride hydrate eye drop one time 1 ~ 2, in instillation eyelid, closes order 3 ~ 5 minutes.Every day 1-3 time.
Accompanying drawing explanation
Fig. 1 is the thermal analyses collection of illustrative plates (embodiment 1) of Berbamine hydrochloride 3 hydrate,
Fig. 2 is the thermal analyses collection of illustrative plates (embodiment 2) of Berbamine hydrochloride 3 hydrate,
Fig. 3 is the thermal analyses collection of illustrative plates (embodiment 3) of Berbamine hydrochloride 3.5 hydrate,
Fig. 4 is the X powder diffraction collection of illustrative plates (embodiment 2) of Berbamine hydrochloride 3 hydrate.
Embodiment
During except there being instruction in an embodiment and separately, in specification sheets and claims, all numerical value used should be understood to be in all examples and modify with term " about ", therefore, unless the contrary indication, numerical parameter given in this specification sheets and appending claims is approximation, it can change according to by character required for sought by present disclosure, at least, and not the application being intended to limit doctrine of equivalents right, each numerical parameter should consider that the number of significant figure and the routine method of rounding up are explained.
Although numerical range and the parameter of the wide region of setting disclosure are approximations.But numerical value given in a particular embodiment is as far as possible accurately reported, any number comprises some error certainly led to by the standard deviation found in their respective tests in essence.
Unless it is pointed out that in literary composition and illustrated in addition clearly, the singulative " " used in this specification and the appended claims, " one " and " being somebody's turn to do " comprise the plural form referring to thing, so, such as.If comprise the mixture of two or more compounds when mentioning the composition containing " a kind of compound ", unless it should be noted that in addition and illustrate in addition clearly herein, term "or" generally includes "and/or".
As used herein, term " obtains " referring to that valuable purity level is separated the compound obtained, and described purity level includes but not limited to be greater than 90%, the purity level of 95%, 96%, 97%, 98% and 99%.Described purity level can pass through high-performance liquid chromatogram determination.
The color of crystalline hydrate that the present invention obtains is the solid between off-white color or pale yellow powder or off-white color-pale yellow powder.
Pharmaceutical composition
" pharmaceutical composition " used herein refers to the composition of medicine, and described pharmaceutical composition can contain the pharmaceutically acceptable carrier of at least one.
" pharmaceutically acceptable vehicle " used herein refers to the pharmaceutical carrier or solvent that are applicable to the compound administration occasionally provided herein, it comprises any examples of such carriers that well known to a person skilled in the art and be applicable to specific administration mode, such as, sterile diluent (such as, water for injection, salts solution, non-volatile wet goods) can be comprised for the solution of parenteral, intradermal, subcutaneous or topical application or suspension agent; The fatty solvent (such as, polyoxyethylene glycol, glycerine, propylene glycol etc.) of synthesis; Antiseptic-germicide (such as, benzylalcohol, to hydroxyl third methyl-formiate, to hydroxyl third ethyl formate etc.); Antioxidant (such as, xitix, sodium bisulfite etc.); Sequestrant (such as, EDTA etc.); Buffer reagent (phosphoric acid salt, Citrate trianion etc.); With or for tonicity-adjusting substances (e.g., sodium-chlor, glucose etc.), or their mixture.Other example comprises, and when intravenous administration, suitable carrier comprises physiological saline, phosphate buffered saline buffer and the solution containing thickening material, such as glucose, polyoxyethylene glycol etc. and their mixture.
As non-limiting example, Berbamine hydrochloride 3 hydrate can optionally and one or more pharmaceutically acceptable mixed with excipients, and can with following form oral administration: tablet, capsule, dispersible powder, granule or the suspensoid containing such as about 0.05-5% suspending agent, or with the form parenteral admin of sterile solution agent or suspensoid, the suspending agent of described suspensoid also containing 0.05-5% in isotonic medium, these pharmaceutical preparations can contain activeconstituents and the carrier of such as about 25% to about 90%, more generally containing 5% to 60%(weight) active ingredient.
In order to understand the present invention further, below in conjunction with embodiment, the preferred embodiment of the invention is described, but should be appreciated that these describe just for further illustrating the features and advantages of the present invention, instead of limiting to the claimed invention.
With specific embodiment, effect of the present invention is described below, but protection scope of the present invention is not limited by the following examples.
Heat analysis method
Thermal analyses test condition: Setaram company Setsys16, about sample size 3-10mg, heat-up rate: 10K/min, N
2flow velocity: 50ml/min, temperature: about room temperature ~ 400 DEG C.
Surprisingly, distinctive, have corresponding endotherm(ic)peak under the weightless platform of thermal analyses (TG-DTA or the TG-DSC) collection of illustrative plates of hydrate of the present invention, thermal analyses collection of illustrative plates demonstrates Berbamine hydrochloride crystalline hydrate; It is worthy of note, the thermal analyses collection of illustrative plates of Berbamine hydrochloride hydrate about heats from room temperature, be a platform to TG curvilinear characteristic approximation behavior between 50 DEG C, almost there is no obvious weightlessness, and show as obvious weightlessness at about 50 DEG C to about 145 DEG C, corresponding endotherm(ic)peak is obvious, and Karl_Fischer method test proves that this weightlessness is water molecules.
Powder X-ray diffraction approach
Utilize D/MX-III AX x ray diffractometer x, voltage: 35kv, electric current: 30mA, sweep velocity: 10 °/min, step-length: 0.02 °/step; Copper target, monochromator: graphite monochromator; Wavelength
diffraction angle 2 θ, sweep limit 3-60 °, determine the x-ray diffractogram of powder of Berbamine hydrochloride crystalline hydrate, and whole peak position is in ± 0.2 ° of 2 θ.Or utilize the D8AdvanceX x ray diffractometer x of German Bruker company, wavelength
diffraction angle 2 θ, sweep limit 3-60 °, measures sample.
In embodiments, powder X-ray diffractometry is utilized to measure, in diffraction angle 2 θ (3-60 °) useful range, Berbamine hydrochloride 3 hydrate of the present invention, 3.5 hydrates can have corresponding eigenwert in the position comprising following 2 θ values:
Embodiment 2(accompanying drawing 4), in the position about 6.37,7.30,9.28,10.32,11.15 of following 2 θ values, 11.67,12.71,13.36,13.80,14.40,15.04,15.64,16.66,17.16,18.30,19.26,19.92,20.71,21.20,23.62,24.61,25.46,26.64,27.14,27.86,29.04,29.97,30.53,31.90,33.45 etc. have characteristic peak
The unsharp place of data on accompanying drawing 4, visible data below, specific as follows in detail:
PEAK:21-pts/ParabolicFilter,Threshold=3.0,Cutoff＝1.0%,BG=3/1.0,Peak-Top=CentroidFit
In another embodiment (embodiment 3), powder X-ray diffractometry is utilized to measure, in diffraction angle 2 θ (3-60 °) useful range, Berbamine hydrochloride 3.5 hydrate of the present invention can have corresponding eigenwert in the position comprising following 2 θ values, about 6.31, 6.84, 7.24, 11.05, 11.61, 12.67, 13.77, 14.31, 14.83, 15.59, 16.56, 17.13, 18.20, 19.02, 19.62, 20.69, 21.13, 21.64, 22.22, 22.68, 23.58, 24.75, 25.37, 25.72, 26.51, 27.08, 27.76, 28.29, 29.26, 30.41, 30.52, 33.37, 37.83.
Specific embodiment
Embodiment 1 Berbamine hydrochloride 3 hydrate be prepared in 250ml flask, add water 60ml, Berbamine hydrate 10g, add 6M hydrochloric acid soln, after being stirred to dissolve, control pH value of solution=about 1.5-3.5, continue stirring about 30 minutes, add proper amount of active carbon, stir, filter, filtrate concentrates, add appropriate Virahol, cooling, place and separate out solid crystal, filter, gained solids make thinner about 30 DEG C dry about 2 days, be placed in the glass desicator being placed with discolour silica gel siccative again to dry under the room temperature of about 20 DEG C, dry 6 hours of about 45 DEG C vacuum (the vacuum meter reading of vacuum drying oven is approximately about 0.08MPa), obtain off-white color to light yellow crystalline powder 8.3g, differentiate: (1) is got product of the present invention and is about 10mg, the 5ml that adds water dissolves, split in two test tubes, bismuth potassium iodide test solution 1 is added in first pipe, namely salmon precipitation is generated, add potassiumiodide iodine test solution 1 in second pipe, namely generate brown precipitate.(2) get product of the present invention and be about 10mg, the 5ml that adds water dissolves, and adds iron trichloride test solution 2 and iron potassuim cyanide test liquid 1, namely aobvious blue.(3) get product of the present invention, add water the solution made containing 40mg in every 1ml, measures, have maximum absorption at the wavelength place of 281nm according to spectrophotometry (China's coastal port two annex IVA); ESI-MS:m/z:609 ［ M+H-2HCl ］
+; Infrared spectra: ν
kBr maxcm
-13393,3038,2942,2799,2842,2707,2630,1610,1588,1514,1439,1419,1355,1280,1218,1170,1115,1081,1062,1019,896,869,843; It is 7.53% that Ka Shi method measures moisture, and thermal analyses collection of illustrative plates: platform weightlessness about 7.44%, this and sample contain the result (theoretical value 7.35%) (see accompanying drawing 1) in limit of error of 3 crystal water.Elemental Analysis theory: C60.41%, H6.58%, N3.81%Cl9.64%; Measured value: C60.29%, H6.69%, N3.94%Cl9.72%.
The preparation of embodiment 2 Berbamine hydrochloride 3 hydrate gets Berbamine 16.1g(by dry product), processing industry ethanol 50ml, water 5ml is in 250ml flask, add the hydrochloric acid soln that concentration is approximately 4M, be stirred to dissolve rear pH value of solution=about 1.2-3.5, continue stirring about 30 minutes, after concentrated, add appropriate Virahol, place, be cooled to about 0 DEG C, place, abundant precipitation to be precipitated, filter, gained solids make thinner about 30 DEG C dry about 2 days, be placed in the glass desicator being placed with discolour silica gel siccative again to dry under the room temperature of about 20 DEG C, about 42 DEG C vacuum-drying 6 hours again, obtain off-white color to faint yellow solid 14.2 grams, with appropriate water, Virahol, ethyl alcohol recrystallization three times, cooling, place, treat that solid is fully separated out, filter, gained solids about 42 DEG C vacuum-dryings 6 hours (vacuum tightness is approximately about 0.08MPa), obtain off-white color solid 7.0 grams, differentiate: (1) is got product of the present invention and is about 10mg, and the 5ml that adds water dissolves, and splits in two test tubes, adds bismuth potassium iodide test solution 1, namely generate salmon precipitation in the first pipe, add potassiumiodide iodine test solution 1 in second pipe, namely generate brown precipitate.(2) get product of the present invention and be about 10mg, the 5ml that adds water dissolves, and adds iron trichloride test solution 2 and iron potassuim cyanide test liquid 1, namely aobvious blue.(3) get product of the present invention, add water the solution made containing 40mg in every 1ml, measures, have maximum absorption at the wavelength place of 281nm according to spectrophotometry (China's coastal port two annex IVA); ESI-MS:m/z:609 ［ M+H-2HCl ］
+; Infrared spectra: ν
kBr maxcm
-13415,3037,2942,2799,2634,1611,1514,1439,1356,1278,1218,1171,1116,1082,1061,1019,896,870,842; It is 7.64% that Ka Shi method measures moisture, thermal analyses TG-DTA: platform weightlessness about 7.44%, and this and sample contain the result (theoretical value 7.35%) (see accompanying drawing, 2) in limit of error of 3 crystal water; X-ray powder diffraction is shown in accompanying drawing 3; Ultimate analysis, theoretical value: C60.41%, H6.58%, N3.81%Cl9.64%; Measured value: C60.32%, H6.67%, N3.96%Cl9.77%.
Berbamine 12.6g is got in the preparation of embodiment 3 Berbamine hydrochloride 3.5 hydrate, add ethanol 50ml, water 5ml is in 250ml flask, add the hydrochloric acid soln that concentration is approximately 6M, be stirred to dissolve rear pH value of solution=about 1.0-3.5, continue stirring about 30 minutes, after concentrated, add appropriate Virahol, place, be cooled to about 0 DEG C, place, abundant precipitation to be precipitated, filter, by the appropriate water of gained solid, Virahol, acetone recrystallization twice, cooling, place, treat that solid is fully separated out, filter, gained solids make thinner about 30 DEG C dry about 1 day, be placed in the glass desicator being placed with discolour silica gel siccative again to dry under the room temperature of about 20 DEG C, dry 6 hours of gained solids about 42 DEG C, obtain off-white color solid 6.1 grams, differentiate: (1) is got product of the present invention and is about 10mg, and the 5ml that adds water dissolves, and splits in two test tubes, adds bismuth potassium iodide test solution 1, namely generate salmon precipitation in the first pipe, add potassiumiodide iodine test solution 1 in second pipe, namely generate brown precipitate.(2) get product of the present invention and be about 10mg, the 5ml that adds water dissolves, and adds iron trichloride test solution 2 and iron potassuim cyanide test liquid 1, namely aobvious blue.(3) get product of the present invention, add water the solution made containing 40mg in every 1ml, measures, have maximum absorption at the wavelength place of 281nm according to spectrophotometry (China's coastal port two annex IVA); ESI-MS:m/z:609 ［ M+H-2HCl ］
+; Infrared spectra: ν
kBr maxcm
-13423,2942,2841,2633,1609,1589,1515,1453,1439,1421,1384,1357,1274,1250,1220,1169,1117,1083,1065,1020,984,895,874,839,808; It is 8.58% that Ka Shi method measures moisture, thermal analyses TG-DTA: platform weightlessness about 8.37%(is shown in accompanying drawing 3), this and sample contain the result (theoretical value 8.47%) of 3.5 crystal water in limit of error; Ultimate analysis, theoretical value: C59.67%, H6.63%, N3.76%Cl9.52%; Measured value: C59.73%, H6.70%, N3.83%Cl9.64%; Powder x-ray diffraction: there is corresponding eigenwert, about 6.31,6.84,7.24,11.05,11.61 in the position comprising following 2 θ values, 12.67,13.77,14.31,14.83,15.59,16.56,17.13,18.20,19.02,19.62,20.69,21.13,21.64,22.22,22.68,23.58,24.75,25.37,25.72,26.51,27.08,27.76,28.29,29.26,30.41,30.52,33.37,37.83.
Embodiment 4 gets Berbamine hydrochloride 3 hydrate 20g, add glucose or N.F,USP MANNITOL or Xylitol 2.0 ~ 5g to add fresh water for injection 420ml and stir, with phosphoric acid or and the sodium hydroxide solution of 1M regulate pH to be 3.0 ~ 5.0, make to be dissolved into solution, add activated carbon 0.01 ~ 0.5%(W/V) stir 15 ~ 45min, filter, moisturizing to 500ml, with 0.22 micrometer Millipore membrane filtration, by 50mg/ bottle, 100mg/ bottle or 200mg/ bottle (in main ingredient) packing, lyophilize, tamponade, obtains finished product.
Embodiment 5 gets Berbamine hydrochloride 3 hydrate 20g, with N.F,USP MANNITOL 40g, add 40-60 DEG C of water for injection 430ml to stir, with the Citric Acid of 1M or and sodium hydroxide regulate pH to be 3.0 ~ 5.0, make to be dissolved into solution, add activated carbon 0.01 ~ 0.5%(W/V) stir 15 ~ 45min, filter, moisturizing is to 500ml, the ultrafiltration membrance filter of relative molecular mass 1000-8000 is retained with 0.22 micrometer Millipore membrane filtration or employing, by 50,100mg/ bottle or 200mg/ bottle (by Berbamine hydrochloride 3 hydrated basis) packing, lyophilize, tamponade, obtains finished product.
The little hydro-acupuncture preparation of embodiment 6 prepare Berbamine hydrochloride hydrate 10.2g (standby or embodiment 2 method of embodiment 1 legal system or embodiment 3 method), add cysteine hydrochloride 0.8g, EDETATE SODIUM 0.1g, injecting blunges makes dissolving, 2M lactic acid and Sodium.alpha.-hydroxypropionate regulate pH to be 3.0 ~ 4.5, add activated carbon 0.01%(W/V) stir 15 ~ 45min, filter, moisturizing is to 500ml, the ultrafiltration membrance filter of relative molecular mass 3000-8000 is retained with 0.22 micrometer Millipore membrane filtration or employing, by the packing of 5ml/ bottle, sterilizing obtains finished product.
Embodiment 7 Berbamine hydrochloride 3 hydrate 10g, inject and stir with water 400ml, with phosphoric acid or and the sodium hydroxide solution of 1M regulate pH to be 2.0 ~ 4.0, make to be dissolved into solution, add activated carbon 0.01%(W/V) stir 15 ~ 45min, filter, moisturizing, to 500ml, retains the ultrafiltration membrance filter of relative molecular mass 3000-10000 with 0.22 micrometer Millipore membrane filtration or employing, by the packing of 5ml/ bottle, lyophilize, tamponade, obtains finished product.
The preparation of embodiment 8 high-capacity injection takes glucose 500g and adds in water for injection, is stirred to dissolve completely, adds the gac of dosing amount 0.05%, heat about 10-30 minute, let cool, through sand stick filtering decarbonization, standby or embodiment 2 method or embodiment 3 method by Berbamine hydrochloride hydrate embodiment 1 legal system) 10.1g, dissolve completely with fresh water for injection, mix with above-mentioned filtrate, add L-cysteine hydrochloride 1g, EDETATE SODIUM 0.2g, by 1M lactic acid solution adjust ph in the scope of 3.2-5.0, inject water to 5000ml, add the gac of dosing amount 0.01%, about heated and stirred 10-30 minute, filtering decarbonization, the ultrafiltration membrance filter of relative molecular mass 3000-2000 is retained again through the filter of 0.22um millipore filtration essence or employing, chemically examine through work in-process, treat its content, pH value and clarity qualified after, embedding is in the vial of 50ml or 100ml or 200ml, sterilizing, finished product inspection, pack and get final product.
The preparation of embodiment 9 Berbamine hydrochloride hydrate sodium-chlor transfusion: by Berbamine hydrochloride hydrate 10g (standby or embodiment 2 method of embodiment 1 legal system or embodiment 3 method), sodium-chlor 85g, Sodium Pyrosulfite 1.1g, EDETATE SODIUM 0.2g, add in water for injection, be stirred to dissolve completely, by the Citric Acid of 1M and liquor sodii citratis adjust ph in the scope of 4.0-6.5, inject water to 10000ml, add the gac of dosing amount 0.05%, about heated and stirred 10-30 minute, filtering decarbonization, the ultrafiltration membrance filter of relative molecular mass 3000-20000 is retained again through the filter of 0.22um millipore filtration essence or employing, chemically examine through work in-process, treat its content, pH value and clarity qualified after, embedding is in the vial of 50ml or 100ml or 200ml, sterilizing, finished product inspection, pack and get final product.
Embodiment 10 Berbamine hydrochloride 3 hydrate tablet (50mg/ sheet)
Berbamine hydrochloride 3 hydrate (embodiment 1 method or embodiment 2 method), Microcrystalline Cellulose, sodium starch glycolate are crossed 100 mesh sieves, with PVP K-30 ethanol water (7:3) the solution softwood processed in right amount of 10%, cross 18-24 mesh sieve to granulate, dry, after crossing the whole grain of 14-20 mesh sieve, add micropowder silica gel mixing, compressing tablet, inspection, packaging.
Embodiment 11 Berbamine hydrochloride hydrate capsule (100mg/ grain)
Berbamine hydrochloride hydrate (standby or embodiment 2 method of embodiment 1 legal system or embodiment 3 method), Microcrystalline Cellulose, lactose are crossed 100 mesh sieves, gelling starch with 10% is softwood processed in right amount, cross 18-24 mesh sieve to granulate, dry, after crossing the whole grain of 14-20 mesh sieve, add Magnesium Stearate mixing, filling capsule.
The granule (100mg/ wraps, by Berbamine hydrochloride 3 hydrated basis) of embodiment 12 Berbamine hydrochloride 3 hydrate
Berbamine hydrochloride 3 hydrate (embodiment 2 legal system is standby), N.F,USP MANNITOL, lactose, Sodium Cyclamate, food flavour are crossed 100 mesh sieves, PVP K-30 aqueous ethanolic solution with 8% softwood processed in right amount, cross 18-24 mesh sieve to granulate, less than 60 DEG C dry, added the xanthan gum of 100 mesh sieves, after crossing the whole grain of 14-20 mesh sieve, mixing, added the xanthan gum of 100 mesh sieves, point packaging.
The eye drop of embodiment 13 acid hydrochloride salt Berbamine 3 hydrate
By Berbamine hydrochloride 3 hydrate 5g (embodiment 2 legal system is standby), glycerine 10ml, PVP K-30 2g, add the water for injection that people is appropriate, after stirring makes it dissolve, again by sodium bisulfite 0.6g, EDETATE SODIUM 0.3g, 5% Benza 1ml, sodium-chlor 3.1g adds people in above-mentioned solution, be stirred to dissolve, 5.0-7.0 is adjusted to sodium hydrogen phosphate and disodium phosphate soln, then people's water for injection is added to 500ml, stir, detect, with 0.22-0.45 μm of filtering with microporous membrane to clear and bright, be sub-packed in sterilized clean eyedrops bottle, sterilizing, let cool, obtain.
Be appreciated that the change of a lot of details is possible, therefore this do not limit the scope of the invention and spirit, and the present invention is not limited to above-described embodiment.
Claims (9)
1. isoquinoline class derivate, is characterized in that: isoquinoline class derivate is Berbamine hydrochloride crystalline hydrate, and its molecular formula is C
37h
40n
2o
62HClnH
2o, wherein n=3.0,3.5.
2. isoquinoline class derivate according to claim 1, is characterized in that: isoquinoline class derivate is Berbamine hydrochloride 3 hydrate.
3. Berbamine hydrochloride 3 hydrate according to claim 2, it is characterized in that: utilize powder X-ray diffractometry to measure, at diffraction angle 2 θ, in the useful range of 3-60 °, in the position of following 2 θ values, there is corresponding eigenwert: 6.37, 7.30, 9.28, 10.32, 11.15, 11.67, 12.71, 13.36, 13.80, 14.40, 15.04, 15.64, 16.66, 17.16, 18.30, 19.26, 19.92, 20.71, 21.20, 23.62, 24.61, 25.46, 26.64, 27.14, 27.86, 29.04, 29.97, 30.53, 31.90, 33.45.
4. isoquinoline class derivate according to claim 1, is characterized in that: isoquinoline class derivate is Berbamine hydrochloride 3.5 hydrate.
5. Berbamine hydrochloride 3.5 hydrate according to claim 4, it is characterized in that: utilize powder X-ray diffractometry to measure, at diffraction angle 2 θ, in the useful range of 3-60 °, in the position of following 2 θ values, there is corresponding eigenwert: 6.31, 6.84, 7.24, 11.05, 11.61, 12.67, 13.77, 14.31, 14.83, 15.59, 16.56, 17.13, 18.20, 19.02, 19.62, 20.69, 21.13, 21.64, 22.22, 22.68, 23.58, 24.75, 25.37, 25.72, 26.51, 27.08, 27.76, 28.29, 29.26, 30.41, 30.52, 33.37, 37.83.
6. prepare isoquinoline class derivate as claimed in claim 1, it is characterized in that:
By Berbamine, be added to the water of 2-12 times amount, C
1-C
6low mass molecule alcohol in one or more reaction vessels in, add hydrochloric acid soln, be stirred to dissolve, between adjust ph to 1.0-3.5, add proper amount of active carbon, stir, filter, filtrate is concentrated, in filtrate, adds C
1-C
6low mass molecule alcohol, C
3-C
8low molecule ketone in one or more, cooling, make crystallization, filter, by gained solid drying, obtain Berbamine hydrochloride crystalline hydrate; By gained Berbamine hydrochloride crystalline hydrate water and C
1-C
6low mass molecule alcohol, C
3-C
8low molecule ketone in one or more, one or many recrystallization operation can be carried out further.
7. in isoquinoline class derivate preparation method as claimed in claim 6, its crystallization or recrystallization solvent are selected from: one or more in water and methyl alcohol, ethanol, Virahol, acetone, hexone.
8. the purposes of isoquinoline class derivate according to claim 1, it is characterized in that: be applicable to preparation injection freeze-dried powder or little water needle injection, great transfusion preparation, application on gastrointestinal administration preparation, dosing eyes preparation, be wherein selected from tablet, capsule, granule through gastrointestinal administration preparation.
9. the purposes of isoquinoline class derivate according to claim 1, is characterized in that: be applicable to prepare following to the application in the caused treatment of humans and animals disease or the medicine of prevention: for the preparation of the application promoted in the medicine of leucocyte hyperplasia, preventing cancer radiotherapy, Leukocytes after Chemotherapy minimizing, anti-inflammatory, tuberculosis, anti-silicosis, antitumor, hypotensive, anti-myocardial anoxia ischemic, antiarrhythmic treatment or prevention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210521407.XA CN103012421B (en) | 2012-12-06 | 2012-12-06 | Iloquinoline derivative medicine and preparation thereof and purposes |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210521407.XA CN103012421B (en) | 2012-12-06 | 2012-12-06 | Iloquinoline derivative medicine and preparation thereof and purposes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103012421A CN103012421A (en) | 2013-04-03 |
| CN103012421B true CN103012421B (en) | 2016-01-20 |
Family
ID=47961573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210521407.XA Expired - Fee Related CN103012421B (en) | 2012-12-06 | 2012-12-06 | Iloquinoline derivative medicine and preparation thereof and purposes |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103012421B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113908160A (en) * | 2021-11-29 | 2022-01-11 | 深圳市第三人民医院(深圳市肝病研究所) | Application of berbamine in anti-mycobacterium tuberculosis drugs |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181932A (en) * | 1996-11-07 | 1998-05-20 | 何浩 | Berbamine used as medicine for preventing and curing cataract |
| US20100298369A1 (en) * | 2009-05-19 | 2010-11-25 | David Horne | Berbamine derivatives |
| CN102002074A (en) * | 2010-11-18 | 2011-04-06 | 浙江大学 | Chemical modification method for glycosylated berbamine new molecule of traditional Chinese medicine berbamine |
| WO2012025054A1 (en) * | 2010-08-27 | 2012-03-01 | 杭州本生药业有限公司 | Diimidated derivative of berbamine, and preparation method therefor and use thereof |
-
2012
- 2012-12-06 CN CN201210521407.XA patent/CN103012421B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1181932A (en) * | 1996-11-07 | 1998-05-20 | 何浩 | Berbamine used as medicine for preventing and curing cataract |
| US20100298369A1 (en) * | 2009-05-19 | 2010-11-25 | David Horne | Berbamine derivatives |
| WO2012025054A1 (en) * | 2010-08-27 | 2012-03-01 | 杭州本生药业有限公司 | Diimidated derivative of berbamine, and preparation method therefor and use thereof |
| CN102002074A (en) * | 2010-11-18 | 2011-04-06 | 浙江大学 | Chemical modification method for glycosylated berbamine new molecule of traditional Chinese medicine berbamine |
Non-Patent Citations (1)
| Title |
|---|
| 盐酸小檗胺的提取及精制;温普红，等;《西北大学学报(自然科学版)》;20011231;第31卷(第6期);第489-491页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103012421A (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5479912B2 (en) | Amorphous form of heterocyclic compound, solid dispersion containing the same, drug, and method for producing the same | |
| US6258821B1 (en) | Compositions comprising trimetrexate and methods of their synthesis and use | |
| CA2874815C (en) | Pharmaceutical compositions comprising rifaximin and amino acids, preparation method and use thereof. | |
| TW201039865A (en) | Lyophilized preparations of proteasome inhibitors | |
| CN102180890B (en) | Cefathiamidine hydrate and preparation method and application thereof | |
| CN101633683B (en) | Antihepatitis medicament, preparation method thereof and use thereof | |
| BR112012009660B1 (en) | liposome having internal water phase containing sulfobutyl ether cyclodextrin salt, its preparation process, its use and liposomal pharmaceutical preparation | |
| CN102180889A (en) | Ceftizoxime sodium crystalline hydrate and preparation method and application thereof | |
| CN104628796A (en) | Gastrodin medicine, and composition and use thereof | |
| CN106957315B (en) | N- replaces benzenesulfonyl-azaindole oxybenzamide class compound and its prepares the purposes of drug | |
| CN103012421B (en) | Iloquinoline derivative medicine and preparation thereof and purposes | |
| US9475759B2 (en) | Tigecycline crystalline hydrate and preparation method therefor and use thereof | |
| CN102250123B (en) | Cefodizime sodium hydrate and application thereof | |
| CN105566316A (en) | Dibenzo quinolizine compound entity and application thereof | |
| WO2007143895A1 (en) | Supersaturated solution of gemcitabine hydrochloride and prepraration method thereof | |
| CN105837646A (en) | Flavonoid new chemical entity, composition and use | |
| CN101525360A (en) | Hydrates of macrolides organic acid salts, preparation and application thereof | |
| CN102911226B (en) | Erythromycin octadecanoate compounds thing entity and uses thereof | |
| CN110551038B (en) | Novel antitumor compounds and uses thereof | |
| CN105367622B (en) | A kind of argatroban compound | |
| KR20160115827A (en) | Preparation comprising indole compound and process for preparing the same | |
| CN108264465B (en) | Dapoxetine hydrochloride monohydrate, preparation method and application thereof | |
| CN105272913A (en) | Isoquinoline compounds and composition and use thereof | |
| CN104402908A (en) | Cefoxitin sodium compound entity and composition and uses thereof | |
| EP4029506B1 (en) | Method for preventing precipitation of injectable solution containing p-boronophenylalanine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160120 Termination date: 20191206 |